Dietary Supplements: An Illusion that became a Delusion

The use of vitamin supplements have become almost a religious belief in our culture. We bought the notion that If some is good, more must be better.

But, there is little evidence of efficacy of vitamins in healthy people who eat a balanced diet. There is however increasing evidence of harm.

After adjustment for multiple potential confounders, use of multivitamins and vitamin B6, folic acid, iron, magnesium, zinc, and copper supplements was associated with greater all-cause mortality through 19 years of follow-up (HRs 1.06 to 1.45), according to Jaakko Mursu, PhD, of the University of Eastern Finland in Kuopio, and colleagues.

Use of a daily calcium supplement, on the other hand, was associated with a lower risk of death (HR 0.91, 95% CI 0.88 to 0.94), the team reported in the Oct. 10 issue of the Archives of Internal Medicine.

And:

“We cannot recommend the use of vitamin and mineral supplements as a preventive measure, at least not in a well-nourished population,” they wrote. “Those supplements do not replace or add to the benefits of eating fruits and vegetables and may cause unwanted health consequences.”


Why Drugs Cost So Much: All Animals Are Equal but Some are More Equal Than Others

The drug industry is lobbying furiously:

The primary trade group for the pharmaceutical industry spent $4.7 million in the second quarter lobbying the federal government on prices that federal health programs pay for prescription medicines and on other issues including patents, drug shortages and reimportation of drugs, according to a quarterly disclosure report.

And:

lobbied on implementation of aspects of the 2010 health care overhaul, including prices and rebates for drugs bought through the Medicare program, strengthening Medicare anti-fraud measures and eliminating an independent payment advisory board meant to hold down Medicare spending.

The article also highlights those former government officials currently lobbying their former colleagues on this issue.

Medicynical Note: Read the article. PhRMA opposes anything that will decrease drug prices. Consumer interest, value, access to less expensive drugs all are opposed by this group.

Since our esteemed Supreme Court ruled that corporations are citizens with equal rights to individuals, it appears that George Orwell’s truism from Animal farm has finally come to fruition. “All animals are equal but some are more equal than others.”


Money Flow, Medicare, Private Insurance, Waste

Interesting Economix by Uwe Reinhardt on money flow in health care:

He notes:

In fairness, it must be added that traditional Medicare basically sets prices and then just pays bills. It makes no active attempt to manage care (utilization controls, disease management, coordinating care and so on), because it has not been allowed by Congress to do so. It is almost as if Congress did not want traditional Medicare to be a prudent purchaser of heath care for the elderly. (Medicynical emphasis)

From the viewpoint of prudent purchasing, most economists would probably judge these prices too low. On the other hand, the fact that traditional Medicare just pays bills more or less passively may be precisely the reason that it is still so popular among the elderly. Traditional Medicare still offers beneficiaries completely free choice of providers and therapy — a degree of freedom that many younger Americans in insurance plans with limited networks of providers no longer enjoy.

Medicynical Note: Until we approach the issue of value in medicine (What works? Bang for the buck?) we’ll have the most expensive least efficient health care non-system in the world. What’s bugging us, the US, now is how to get to such a system.

Is health care part of the package of being a US citizen? Providing Medicare to the elderly and many with chronic illness implies such a commitment. Does required access to ER care for all, whether they can pay or not, point to a civic responsibility to assure access to care to the rest of the population?

If our republican friends really believe that health care is not a “right” then a large swath of citizenry are going to be in trouble as republicans follow through on this philosophy. Interestingly these rightist purists for some reason tout ER access for all as adequate health care in our non-system. Why they would choose the most expensive, least efficient care in the world as their means of providing health care is unknown.

If there is an explicit right to health care in our country, more efficient ways to provide it must be found. It should assure affordable care to citizens, including the elderly and those with illnesses. One problem has been that private insurers, ironically, want little to do with either of those populations.


America’s Ass-Backward Non System of Health Care — Controlling ER visits

You may have heard from Rush Limbaugh and others on the right that we already have a system of health care. That is, emergency room care is available to everyone whether they can pay or not.

What’s not said is that this care is the least efficient and most expensive in the world. And that these unpaid costs are ultimately borne by the local hospital, other patients and other insurers–private as well as Medicare. This raises the cost of health care to all of us. I can’t imagine any thinking person would think this an adequate solution–except as noted above.

Now Washington State, offers a brilliant solution to the problem, by limiting ER visits to 3/year for people covered with Medicaid.

The trouble is all in how you define an emergency.

And:

If a condition is left unspecified, that means it turned out to not be connected to a more dangerous ailment such as a heart attack or stroke. But doctors say that result can’t be known until patients are treated.

“Do (patients) know the difference necessarily between heartburn, heart attack, a blood clot in my lungs and a sore rib?” asked Dr. Stephen Anderson, president of the American College of Emergency Physicians’ state chapter. “These people shouldn’t be sitting at home trying to self-diagnose.

Medicynical Note: Rather than provide outpatient care for these patients as an alternative to ER care and thereby encourage use of more cost effective facilities, we simply cut off all access. Amazing.

This non solution leaves the ER’s and hospitals with a financial problem. Medicaid patients with chest pain that is non cardiac and other problems that turn out not to be “serious” will not be covered by Medicaid . Other patients without any insurance will continue to use ER’s and accrue bills that will not be paid. The cost of their care will still be passed through to other patients and insurers.

The solution solves nothing and simply avoids facing the fundamental issue in our non-system of care–that it is not a system.

Too Much Health Care? Primary Care Physicians Views

A recent Archives of Internal Medicine study of primary care physicians noted:

Forty-two percent of US primary care physicians believe that patients in their own practice are receiving too much care; only 6% said they were receiving too little. The most important factors physicians identified as leading them to practice more aggressively were malpractice concerns (76%), clinical performance measures (52%), and inadequate time to spend with patients (40%). Physicians also believe that financial incentives encourage aggressive practice: 62% said diagnostic testing would be reduced if it did not generate revenue for medical subspecialists (39% for primary care physicians).

It was also noted in a Reuter’s piece about the Archives article that:

Four in 10 also believed that other primary care physicians would order fewer tests if those tests didn’t provide extra income. (Of course, just three percent thought that financial considerations influenced their own practice style.)

“I’m not saying that physicians do tests in order to make money — there is a potential to be a real cynic here — but I think that the reimbursement model for most healthcare encourages utilization in a variety of way,” Sirovich said.

Medicynical Note: It’s not cynical to acknowledge reality.


U.S. Healthcare Leads the World in Preventable deaths

The United States placed last among 16 high-income, industrialized nations when it comes to deaths that could potentially have been prevented by timely access to effective health care, according to a Commonwealth Fund–supported study that appeared online in the journal Health Policy this week and will be available in print on October 25th as part of the November issue. According to the study, other nations lowered their preventable death rates an average of 31 percent between 1997–98 and 2006–07, while the U.S. rate declined by only 20 percent, from 120 to 96 per 100,000. At the end of the decade, the preventable mortality rate in the U.S. was almost twice that in France, which had the lowest rate—55 per 100,000.

Another way to look at this is that we’re number one.


Medicynical Note: U.S. Health Care leads the world in cost/capita, bankruptcies related to medical problems, drug costs, number of procedures done/capita, and now the number of people dying because they don’t have access to timely health care.

Cancer Treatment — Unaffordable, less effective than advertised!

Lancet Oncology (behind pay wall) published a symposium on the “culture of excess” in the treatment of cancer. The BBC notes:

A group of 37 leading experts from around the world say the burden of cancer is growing and becoming a major financial issue.

“The issue that concerns economists and policymakers is not just the amount of money spent on healthcare, but also the rate of increase in healthcare spending or what has become known as the cost curve.”

It says the UK’s total spend on breast cancer has increased by about 10% in each of the past four years.

“Few treatments or tests are clear clinical winners, with many falling into the category of substantial cost for limited benefit.”

The cost of drugs is not the only target for criticism. Lead author Prof Richard Sullivan told the BBC: “It’s not just pharmaceuticals. Biomarkers, imaging and surgery are all getting through with very low levels of evidence – the hurdles are set too low.”

Medicynical Note: It’s too bad this is behind a pay-wall. Patients in the US are subjected to a blizzard of misinformation regarding cancer treatment, outcomes and the “benefits” of different approaches. Costs are not an apparent consideration by providers, patients or insurers and expenditures for cancer care are rising at an unsustainable rate.

We hear about the improved survival of patients and believe that justifies the increased costs. However, most, if not all, of these improvements in survival come from earlier diagnosis of cancers and counting pre-cancerous lesions also found by screening in the cure rate. DCIS, Gleason 5 prostate cancers, and early colon cancers are automatic cures.

The decreased incidence (declining rates) of lung and a few other cancers have little to do with treatment and are a benefit of smoking cessation and in some instances other lifestyle changes.

The new mega-expensive treatments ($50,000-$120,000/year) in patients with bad disease have resulted in no cures and limited survival benefit. Uncritical use of these drugs is bankrupting our non-system of care.

Finally, we still have 20-25% of our population smoking. This fact may provide income security for the medical industrial complex but offers an opportunity for a prevention strategy with real impact.


Cheaper Generics–An Answer To Patent Abuse

It’s been a long time coming but companies in China and in other emerging economies are finally tiring of the outrageous pricing of drugs by U.S. and other western drug manufacturers. Charging more for a drug, than people earn is not an acceptable business practice in my view. Blackmail would be a more honorable business practice than the drug companies practice of charging more for drugs that might benefit (most don’t have a significant effect) those with serious life threatening illness.

So, it appears drug manufacturers elsewhere are producing these new drugs at a fraction of the cost.

Chinese and Indian drug makers have taken over much of the global trade in medicines and now manufacture more than 80 percent of the active ingredients in drugs sold worldwide. But they had never been able to copy the complex and expensive biotech medicines increasingly used to treat cancer, diabetes and other diseases in rich nations like the United States — until now.

Medicynical Note: 80% of the world market supplied by drugs made in China and India. Amazing.

The Best Congress Money Can Buy

House Speaker Boehner invited the president of Pathway Genomics to the president’s speech last night. Pathway was chosen because:

Pathway was chosen because it and the others “exemplify businesses and sectors hurt by excessive Washington-imposed barriers preventing them from innovating, growing and creating more jobs.”

But Pathway’s product a genetic test was flawed:

However, reports by the independent Government Accountability Office (GAO) and the Food and Drug Administration indicate the product Boehner, R-Ohio, claimed was unfairly maligned by federal regulators was unapproved and ineffective.

And:

Reports from the FDA, GAO and the medical community show there’s no proof the tests actually work.

Jeffrey Shuren, director of the FDA’s Center for Devices and Radiological Health, told a House committee in July 2010 that he had seen faulty data analysis, exaggerated clinical claims, fraudulent data and unacceptable clinical performance associated with the tests.

“These tests have not been proven safe, effective or accurate,” Shuren said.

It should be noted that the CEO of Pathway, earlier this year, participated in a republican sponsored “job” forum and is undoubtedly a contributor to the republican “cause.”

Medicynical Note: Science? Facts? Proof of efficacy? Apparently are not the House Speaker’s concern.

Businesses needs regulation to not only protect the consumer but to protect themselves, from themselves–see financial crisis 2007-2009.


Health Care Cost Growth and Income Gains

Back from a wonderful trip to Botswana and Zambia.

I noted a remarkably skewed analysis of the impact of the health care bubble on gains in household income the last ten years in Health Affairs.

They note:

Although a median-income US family of four with employer-based health insurance saw its gross annual income increase from $76,000 in 1999 to $99,000 in 2009 (in current dollars), this gain was largely offset by increased spending to pay for health care. Monthly spending increases occurred in the family’s health insurance premiums (from $490 to $1,115), out-of-pocket health spending (from $135 to $235), and taxes devoted to health care (from $345 to $440). After accounting for price increases in other goods and services, the family had $95 more in monthly income to devote to nonhealth spending in 2009 than in 1999.

The analysis is unrealistic and understates the impact of health inflation by focusing primarily on those with employer based insurance. The population without such insurance has almost certainly lower income and higher insurance costs, if they are covered at all.

More here:

Copays have increased as well, the authors pointed out. In 1999, the average copay for a doctor’s visit was in the range of $5 to $10, but by 2009, it ranged from $20 to $30. Copays for visits to the emergency room were rare in 1999, but a decade later, they cost $100 or more.

In addition, taxes devoted to healthcare — for Medicare, Medicaid, the military health system, and the Department of Veterans Affairs — increased from $345 to $440 from 1999 to 2009, Auerbach and Kellerman wrote. They added that the tax hike is “misleadingly modest” because actual growth in government spending on healthcare was much larger: 140% at the federal level and 76% at the state level. The authors said Bush-era tax cuts caused the government to collect only $6 for every $10 it spent during that 10-year time frame. (medicynical emphasis)

Medicynical note: The median household income in the US is significantly lower than stated in this article which as noted refers to those with employer based health insurance. It approximates $60,000 and has not risen much if at all over the past ten years.

As we’ve emphasized previously health care costs over ten years have inflated by 130%.

It’s amazing how much more we pay for health care than any other place in the world. It’s dubious that this will change dramatically in the near future with both parties in the pay of the medical industrial complex–though I still hold out hope that health reform is a first step toward cost containment.